In cohorts of female breast cancer survivors with assessments of biomarkers up to 1 year postsurgery, higher levels of fasting insulin, compared to lower levels, have been associated with increased recurrences,29, 30, 31 cancer‐specific deaths,32 and all‐cause mortality.30 This evidence concerns the gene INS and cancer.